The FDA's approvals database records a supplement approved on 14 October to the biologics licence for etanercept (Enbrel, BLA 103795). The public record does not state what changed.
Etanercept is a TNF inhibitor used in rheumatological and dermatological disease. It is not used to treat inflammatory bowel disease, where it was ineffective in Crohn's disease, and it has been linked to new-onset IBD in some reports.
For gastroenterologists, there is nothing new to act on; the practical relevance remains recognising IBD-like symptoms in patients taking it.
- FDA approved a supplement for etanercept on 14 October
- The public record does not describe the change
- Etanercept is not an IBD treatment
- Consider IBD in a patient on etanercept with new bowel symptoms
Why it matters
It avoids reading an administrative entry as news about IBD therapy.
Don't overread it
A licence supplement is not a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free